ANPCY News and Press, Angle Plc Surrey ADR From 05/12/20

MET EXPRESSION OF PARSORTIX-HARVESTED CTCs FROM CANCER PATIENTS HAS POTENTIAL AS BIOMARKER FOR MET INHIBITOR DRUG TRIALS Potential for liquid biopsy solution to drive new areas of cancer treatment Parsortix performance demonstrates key advantages over alternative approaches G...

LEADING CANCER CENTRE PUBLISHES PARSORTIX WORKFLOW ADDRESSING PROBLEMS WITH ALTERNATIVE APPROACHES Workflow for RNA gene expression demonstrated in prostate cancer Researchers show that "previously undetectable prostate specific transcripts become readily measurable" GUIL...

Progress across multiple fronts In-house capability developed to determine CTC PDL1 status for immunotherapy trials COVID-19 highlights crucial need for liquid biopsy for cancer patients GUILDFORD, SURREY / ACCESSWIRE / April 28, 2020 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a wo...

PARSORTIX PERFORMANCE DEMONSTRATED IN HEAD AND NECK CANCER Molecular analysis demonstrates measurement of key cancer genes and methylation status from a simple blood test Direct comparison highlights key advantages of Parsortix compared to antibody-based approach GUILDFORD, S...

GUILDFORD, SURREY / ACCESSWIRE / March 31, 2020 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, provides an update in relation to the impact of the Coronavirus (COVID-19) pandemic on its business. ANGLE's operations and activities in the UK, Canada and the US have...

PARSORTIX OUTPERFORMS OTHER CTC SYSTEMS IN RENAL CELL CARCINOMA Publication in International Journal of Molecular Sciences demonstrates benefits of Parsortix "unbiased" CTC enrichment process Workflow combines Parsortix with downstream process for single cell analysis of each indiv...

ANGLE AND BIOVIEW TO PRESENT COMBINED SOLUTION FOR CIRCULATING TUMOR CELL DETECTION AND ANALYSIS AT MOLECULAR MED TRI-CON 2020 IN SAN FRANCISCO, 4 MARCH 2020 GUILDFORD, SURREY / ACCESSWIRE / February 25, 2020 / ANGLE plc, (AIM:AGL)(OTCQX:ANPCY) a world leading liquid biopsy company, and B...

Hamburg-Eppendorf developed validated standardised Parsortix protocols for use in future clinical trials Parsortix harvested cells allow for "robust amplification of single cell DNA at excellent quality for subsequent molecular analysis" GUILDFORD, ENGLAND / ACCESSWIRE / Februa...

NEW STUDY DEMONSTRATES POTENTIAL FOR PARSORTIX IN MELANOMA PROGNOSTICATION AND TREATMENT RESPONSE Parsortix out-performed alternative systems in head to head comparisons and was selected for molecular analysis in the study Parsortix CTC score linked to progression-free and overall surv...

ANGLE plc ( OTCQX:ANPCY ): 1H GAAP EPS of -3.33p. More news on: ANGLE plc, ANGLE plc, Earnings news and commentary, Healthcare stocks news, , Read more ...